Ocular Therapeutix, Inc (OCUL): Capital Expenditures
$12.01M
Year ended 2025-12-31
$16.86M
Trailing 12 months to 2026-06-30
+47.9%
3-year compound annual growth
+70.2%
5-year compound annual growth
+21.0%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.01M | +832.5% | 2026-02-05, From 2025-01-01 |
| 2024-12-31 | $1.29M | -78.8% | 2026-02-05, From 2024-01-01 |
| 2023-12-31 | $6.09M | +63.8% | 2026-02-05, From 2023-01-01 |
| 2022-12-31 | $3.71M | +211.1% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $1.19M | +42.0% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $841.0K | -62.4% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $2.24M | +18.5% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $1.89M | -77.1% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $8.25M | +330.0% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $1.92M | +7.9% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $1.78M | +41.1% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $1.26M | +225.6% | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | $387.0K | +90.6% | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | $203.0K | n/a | 2015-03-20, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $12.01M | +832.5% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $0 | -100.0% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $4.32M | +156.1% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $0 | -100.0% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $171.0K | -88.4% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $79.0K | n/a |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $29.0K | -87.3% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $1.59M | +17.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $518.0K | -75.4% |
Compare OCUL, QTTB, AGIO, LXRX side by side · Screen every company in Pharmaceutical Preparations ↗